13D Filing: Bay City Capital Fund V, L.P. and Sunesis Pharmaceuticals Inc (SNSS)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
BAY CITY CAPITAL FUND V 0 1,828,968 0 1,828,968 1,828,968 5.3%
BAY CITY CAPITAL FUND V CO-INVESTMENT FUND 0 1,828,968 0 1,828,968 1,828,968 5.3%
BAY CITY CAPITAL MANAGEMENT V 1,828,968 0 1,828,968 0 1,828,968 5.3%
BAY CITY CAPITAL 1,828,968 0 1,828,968 0 1,828,968 5.3%

Page 1 of 13 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)*

 

 

Sunesis
Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

867328700

(CUSIP Number)

Susan Vuong

Chief Financial Officer

Bay City Capital LLC

750
Battery Street, Suite 400

San Francisco, California 94111

(415) 676-3830

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 27, 2017

(Date of Event Which Requires Filing of This Statement)

 

 

If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box.  ☐

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)